Name | Number of supported studies | Average coverage | |
---|---|---|---|
peripheral blood | 12 studies | 22% ± 6% | |
lung | 10 studies | 26% ± 7% | |
intestine | 7 studies | 20% ± 9% | |
brain | 6 studies | 33% ± 11% | |
liver | 6 studies | 28% ± 16% | |
kidney | 5 studies | 20% ± 2% | |
bone marrow | 4 studies | 22% ± 4% | |
uterus | 4 studies | 28% ± 13% | |
lymph node | 4 studies | 19% ± 2% | |
adipose | 4 studies | 18% ± 3% | |
eye | 3 studies | 23% ± 8% | |
breast | 3 studies | 23% ± 8% | |
prostate | 3 studies | 19% ± 3% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
breast | 100% | 7988.93 | 459 / 459 | 100% | 37.08 | 1118 / 1118 |
esophagus | 100% | 6824.98 | 1445 / 1445 | 100% | 40.20 | 183 / 183 |
intestine | 100% | 6586.52 | 966 / 966 | 100% | 34.11 | 527 / 527 |
ovary | 100% | 8428.29 | 180 / 180 | 100% | 28.72 | 430 / 430 |
prostate | 100% | 6149.91 | 245 / 245 | 100% | 27.31 | 502 / 502 |
stomach | 100% | 5374.83 | 359 / 359 | 100% | 32.09 | 286 / 286 |
lung | 100% | 8337.19 | 578 / 578 | 100% | 31.18 | 1154 / 1155 |
skin | 100% | 10452.70 | 1809 / 1809 | 100% | 29.47 | 470 / 472 |
uterus | 100% | 7709.48 | 170 / 170 | 100% | 33.68 | 457 / 459 |
brain | 99% | 3614.01 | 2628 / 2642 | 100% | 24.05 | 705 / 705 |
bladder | 100% | 7095.24 | 21 / 21 | 99% | 29.02 | 501 / 504 |
thymus | 100% | 6521.37 | 653 / 653 | 99% | 21.26 | 601 / 605 |
liver | 100% | 4949.55 | 226 / 226 | 99% | 18.16 | 401 / 406 |
kidney | 100% | 4900.60 | 89 / 89 | 98% | 24.44 | 885 / 901 |
pancreas | 99% | 4364.37 | 326 / 328 | 98% | 24.57 | 175 / 178 |
adrenal gland | 100% | 6280.16 | 258 / 258 | 96% | 17.53 | 221 / 230 |
adipose | 100% | 8437.63 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 6258.59 | 1335 / 1335 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 41.48 | 29 / 29 |
muscle | 100% | 8598.47 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 7397.11 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 41.04 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 6.45 | 1 / 1 |
heart | 99% | 4529.77 | 850 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 96% | 18.39 | 77 / 80 |
peripheral blood | 81% | 5360.16 | 752 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0032508 | Biological process | DNA duplex unwinding |
GO_0007265 | Biological process | Ras protein signal transduction |
GO_0034063 | Biological process | stress granule assembly |
GO_0045087 | Biological process | innate immune response |
GO_0051607 | Biological process | defense response to virus |
GO_0062029 | Biological process | positive regulation of stress granule assembly |
GO_0032481 | Biological process | positive regulation of type I interferon production |
GO_0090090 | Biological process | negative regulation of canonical Wnt signaling pathway |
GO_0043204 | Cellular component | perikaryon |
GO_0005925 | Cellular component | focal adhesion |
GO_0005829 | Cellular component | cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_1990904 | Cellular component | ribonucleoprotein complex |
GO_0010494 | Cellular component | cytoplasmic stress granule |
GO_0005634 | Cellular component | nucleus |
GO_0003677 | Molecular function | DNA binding |
GO_0004519 | Molecular function | endonuclease activity |
GO_0003724 | Molecular function | RNA helicase activity |
GO_0043024 | Molecular function | ribosomal small subunit binding |
GO_0033677 | Molecular function | DNA/RNA helicase activity |
GO_0003729 | Molecular function | mRNA binding |
GO_0140693 | Molecular function | molecular condensate scaffold activity |
GO_0003678 | Molecular function | DNA helicase activity |
GO_0005524 | Molecular function | ATP binding |
GO_0003723 | Molecular function | RNA binding |
GO_0005515 | Molecular function | protein binding |
GO_0016887 | Molecular function | ATP hydrolysis activity |
Gene name | G3BP1 |
Protein name | GTPase activating protein (SH3 domain) binding protein 1 G3BP stress granule assembly factor 1 (Ras GTPase-activating protein-binding protein 1) G3BP stress granule assembly factor 1 Ras GTPase-activating protein-binding protein 1 (G3BP-1) (EC 3.6.4.12) (EC 3.6.4.13) (ATP-dependent DNA helicase VIII) (hDH VIII) (GAP SH3 domain-binding protein 1) |
Synonyms | G3BP |
Description | FUNCTION: Protein involved in various processes, such as stress granule formation and innate immunity . Plays an essential role in stress granule formation . Stress granules are membraneless compartments that store mRNAs and proteins, such as stalled translation pre-initiation complexes, in response to stress . Promotes formation of stress granules phase-separated membraneless compartment by undergoing liquid-liquid phase separation (LLPS) upon unfolded RNA-binding: functions as a molecular switch that triggers RNA-dependent LLPS in response to a rise in intracellular free RNA concentrations . Also acts as an ATP- and magnesium-dependent helicase: unwinds DNA/DNA, RNA/DNA, and RNA/RNA substrates with comparable efficiency . Acts unidirectionally by moving in the 5' to 3' direction along the bound single-stranded DNA . Unwinds preferentially partial DNA and RNA duplexes having a 17 bp annealed portion and either a hanging 3' tail or hanging tails at both 5'- and 3'-ends . Plays an essential role in innate immunity by promoting CGAS and RIGI activity . Participates in the DNA-triggered cGAS/STING pathway by promoting the DNA binding and activation of CGAS . Triggers the condensation of cGAS, a process probably linked to the formation of membrane-less organelles . Enhances also RIGI-induced type I interferon production probably by helping RIGI at sensing pathogenic RNA . May also act as a phosphorylation-dependent sequence-specific endoribonuclease in vitro: Cleaves exclusively between cytosine and adenine and cleaves MYC mRNA preferentially at the 3'-UTR . . |
Accessions | Q32P45 ENST00000678825.1 ENST00000522761.6 [Q13283-1] ENST00000676827.1 [Q13283-1] A0A7P0P2U7 A0A7I2YQN9 ENST00000677608.1 ENST00000677381.1 [Q13283-2] A0A7I2V2S5 ENST00000678854.1 ENST00000677687.1 ENST00000677493.1 A0A7I2YQM1 A0A7I2V565 ENST00000678500.1 A0A7I2YQP3 A0A7I2V326 ENST00000678372.1 A0A7I2V651 E5RH42 ENST00000676978.1 [Q13283-1] A0A7I2YQR4 ENST00000677408.1 ENST00000678070.1 [Q13283-1] ENST00000677211.1 ENST00000676590.1 A0A7I2V274 ENST00000676899.1 A0A7I2V3C4 ENST00000356245.8 [Q13283-1] ENST00000676507.1 A0A7I2V4D8 A0A7I2V496 ENST00000679289.1 A0A7I2YQQ8 E5RIF8 A0A7I2V5M7 ENST00000677369.1 A0A7I2V2V1 ENST00000523519.5 A0A7I2V533 A0A7I2V548 ENST00000678101.1 [Q13283-1] A0A7I2V2X7 Q13283 E5RI46 ENST00000678976.1 ENST00000678194.1 ENST00000678657.1 ENST00000676813.1 ENST00000678612.1 ENST00000520006.2 ENST00000517947.5 A0A7I2V3V2 ENST00000676734.1 ENST00000677105.1 A0A7I2V3Y4 ENST00000677146.1 ENST00000677854.1 ENST00000678910.1 ENST00000522666.1 ENST00000522367.6 [Q13283-2] ENST00000522761 ENST00000678925.1 [Q13283-1] ENST00000520578.6 ENST00000677923.1 A0A7I2YQB1 ENST00000678646.1 ENST00000676644.1 ENST00000677658.1 ENST00000678726.1 ENST00000520177.6 ENST00000677323.1 [Q13283-1] ENST00000394123.7 [Q13283-1] ENST00000678295.1 A0A7I2V5H1 ENST00000676878.1 A0A7I2YQU8 ENST00000627077.2 ENST00000677284.1 A0A7I2V494 ENST00000679004.1 A0A7I2YQC2 A0A7I2YQH0 ENST00000678964.1 ENST00000677433.1 E5RH00 E5RJU8 A0A7I2V4Y8 ENST00000676715.1 A0A7I2YQF2 ENST00000679135.1 ENST00000678564.1 |